Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ARMEEN MAHVASH and AHMED KASEB.
Connection Strength

2.504
  1. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
    View in: PubMed
    Score: 0.806
  2. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:1-7.
    View in: PubMed
    Score: 0.547
  3. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
    View in: PubMed
    Score: 0.243
  4. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
    View in: PubMed
    Score: 0.220
  5. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):451-461.
    View in: PubMed
    Score: 0.161
  6. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
    View in: PubMed
    Score: 0.151
  7. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875.
    View in: PubMed
    Score: 0.057
  8. Multimodality annotated hepatocellular carcinoma data set including pre-?and post-TACE with imaging segmentation. Sci Data. 2023 01 18; 10(1):33.
    View in: PubMed
    Score: 0.055
  9. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181.
    View in: PubMed
    Score: 0.051
  10. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131.
    View in: PubMed
    Score: 0.047
  11. Planning dosimetry for 90 Y radioembolization with glass microspheres: Evaluating the fidelity of 99m Tc-MAA and partition model predictions. Med Phys. 2020 Oct; 47(10):5333-5342.
    View in: PubMed
    Score: 0.047
  12. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019 Sep; 1(5).
    View in: PubMed
    Score: 0.044
  13. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J Clin Med. 2018 Apr 14; 7(4).
    View in: PubMed
    Score: 0.040
  14. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:55-61.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.